Zealand Pharma A/S

As of June 30, 2026, Zealand Pharma A/S carries a market capitalization of 2.64B, placing it among publicly traded companies globally. Its enterprise value stands at 761.69M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zealand Pharma A/S's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Zealand Pharma A/S has 69.39M shares outstanding.

As of June 30, 2026, Zealand Pharma A/S trades at a trailing price-to-earnings ratio of 7.32. The price-to-sales ratio is 4.32, and the price-to-book ratio stands at 1.10.

As of June 30, 2026, Zealand Pharma A/S trades at an EV/EBITDA multiple of 2.39 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 2.42 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 761.69M versus a market cap of 2.64B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Zealand Pharma A/S maintains a current ratio of 13.98, meaning it holds 14.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.28, indicating elevated leverage, while an interest coverage ratio of 88.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S posted a return on equity (ROE) of 16.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.93 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 14.83, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.07, useful for judging operating efficiency across full business cycles. The company generates approximately 1.40M in revenue per employee across its workforce of 444.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S recorded 13.26M in income tax expense. That works out to an effective tax rate of 3.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 379.84M, leaving 366.58M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Zealand Pharma A/S's stock has declined approximately 51.58% over the past 52 weeks. The 50-day moving average sits at 37.54, while the 200-day moving average is 41.95.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S generated 621.32M in revenue and converted that into 366.58M in net income, yielding earnings per share of 5.19. EBITDA reached 319.05M, while operating income came in at 334.80M.

As of June 30, 2026, Zealand Pharma A/S holds 1.93B in cash and equivalents against 54.99M in total debt, resulting in a net debt position of -498.56M. Total book value stands at 2.41B, with working capital of 2.32B providing operational flexibility.

Zealand Pharma A/S produced -234.57M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.45M in capital expenditures, free cash flow totaled -245.02M - equivalent to -3.48 per share.

Over the twelve months ended June 30, 2026, Zealand Pharma A/S posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of 53.88 and net profit margin of 59.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.12: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 2.58, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Zealand Pharma A/S shareholders.

As of June 30, 2026, Zealand Pharma A/S has an Altman Z-Score of 8.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.